OTCMKTS:ALPMY - ASTELLAS PHARMA/ADR Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.3750 +0.12 (+0.79 %) (As of 02/20/2019 12:35 PM ET)Previous Close$15.25Today's Range$15.3240 - $15.4052-Week Range$12.41 - $17.99Volume15,202 shsAverage Volume94,723 shsMarket Capitalization$30.44 billionP/E Ratio15.72Dividend Yield1.84%Beta0.88 ProfileDiscussionAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. Receive ALPMY News and Ratings via Email Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ALPMY Previous Symbol CUSIPN/A Webwww.astellas.com Phone813-3244-3000Debt Debt-to-Equity Ratio0.04 Current Ratio1.89 Quick Ratio1.56Price-To-Earnings Trailing P/E Ratio15.72 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.00 billion Price / Sales2.54 Cash Flow$1.0284 per share Price / Cash Flow14.95 Book Value$5.78 per share Price / Book2.66Profitability EPS (Most Recent Fiscal Year)N/A Net Income$1.55 billion Net Margins16.27% Return on Equity16.38% Return on Assets11.17%Miscellaneous Employees16,617 Outstanding Shares1,980,000,000Market Cap$30.44 billion OptionableNot Optionable ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions What is ASTELLAS PHARMA/ADR's stock symbol? ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY." When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work? ASTELLAS PHARMA/ADR's stock split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split. How were ASTELLAS PHARMA/ADR's earnings last quarter? ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) released its quarterly earnings results on Wednesday, April, 25th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.15 by $0.05. The firm earned $2.78 billion during the quarter. ASTELLAS PHARMA/ADR had a net margin of 16.27% and a return on equity of 16.38%. View ASTELLAS PHARMA/ADR's Earnings History. When is ASTELLAS PHARMA/ADR's next earnings date? ASTELLAS PHARMA/ADR is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for ASTELLAS PHARMA/ADR. What is the consensus analysts' recommendation for ASTELLAS PHARMA/ADR? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ASTELLAS PHARMA/ADR. Has ASTELLAS PHARMA/ADR been receiving favorable news coverage? Headlines about ALPMY stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ASTELLAS PHARMA/ADR earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of ASTELLAS PHARMA/ADR's key competitors? Some companies that are related to ASTELLAS PHARMA/ADR include AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Allergan (AGN), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN) and Shiseido (SSDOY). Who are ASTELLAS PHARMA/ADR's key executives? ASTELLAS PHARMA/ADR's management team includes the folowing people: Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 59)Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Corp. Exec.Ms. Linda Friedman, Gen. Counsel & VPDr. Sef P. Kurstjens, Chief Medical Officer and Pres of Global Devel. (Age 56) How do I buy shares of ASTELLAS PHARMA/ADR? Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ASTELLAS PHARMA/ADR's stock price today? One share of ALPMY stock can currently be purchased for approximately $15.3750. How big of a company is ASTELLAS PHARMA/ADR? ASTELLAS PHARMA/ADR has a market capitalization of $30.44 billion and generates $12.00 billion in revenue each year. ASTELLAS PHARMA/ADR employs 16,617 workers across the globe. What is ASTELLAS PHARMA/ADR's official website? The official website for ASTELLAS PHARMA/ADR is http://www.astellas.com. How can I contact ASTELLAS PHARMA/ADR? ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000. MarketBeat Community Rating for ASTELLAS PHARMA/ADR (OTCMKTS ALPMY)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 164 (Vote Outperform)Underperform Votes: 123 (Vote Underperform)Total Votes: 287MarketBeat's community ratings are surveys of what our community members think about ASTELLAS PHARMA/ADR and other stocks. Vote "Outperform" if you believe ALPMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: How accurate is the Rule of 72?